FDA Issues Form 483 to Hetero Labs Following Inspection Revealing Severe GMP Violations at Undisclosed Warehouse
核心洞察
The FDA issued a Form 483 to Hetero Labs following a September 2025 inspection that revealed an undisclosed warehouse storing APIs and intermediates for US markets with severe GMP violations.
Inspectors documented pest infestations including birds, lizards, and cats among API drums, along with bird droppings on containers and nests within warehouse structures.
The facility operated without quality oversight, standard operating procedures, or environmental controls, with expired materials commingled with fresh batches and no traceability systems.
The US FDA (搜索) has issued a Form 483 to Hetero Labs Limited following a September 19-26, 2025 inspection that uncovered severe Good Manufacturing Practice (GMP) violations at an undisclosed warehouse facility storing active pharmaceutical ingredients (搜索) (APIs) and intermediates destined for the American market. The inspection revealed widespread non-compliance issues including pest infestations, missing documentation, and complete absence of quality oversight.
Inspection Access Denied, Staff Fled Facility
The FDA inspection began with unusual circumstances when warehouse personnel denied inspectors entry for approximately two hours. According to the Form 483 issued to Mr. Naresh Reddy, Corporate Quality Assurance Senior Manager at Hetero Labs, "Employee personnel, who were later identified as the Assistant Warehouse Manager and Warehouse Staff, had ran out of plain sight upon announcing our intent to inspect the facility."
FDA investigators observed that warehouse gates were abruptly shut and access was blocked. A truck full of drums was seen at the loading dock but was driven away once inspectors arrived, with another incoming truck turned back by security. "The truck full of drums had left the facility without any explanation provided," the report stated.
Undisclosed Facility Storing US-Bound Materials
The warehouse was found to be "undisclosed with the U.S. FDA" despite holding APIs and intermediates for US FDA (搜索) registered manufacturing facilities. The agency noted that Hetero Labs "failed to document the incoming receipt of these materials and perform a visual examination to ensure correct and complete labeling."
Inspectors documented Hetero Unit IX-labeled drums with defaced, handwritten, and partially torn labels, with no traceability or quality documentation. In one instance, recovery material was stored in drums labeled for an entirely different batch, representing a major traceability breach. The Form 483 noted there was "no documentation for the practice of defacing, cutting, and replacing original Hetero Unit IX drum labels with handwritten labels that do not include indication of the manufacturer name, customer's name, required storage conditions and grade designation."
Complete Absence of Quality Systems
Perhaps most concerning, the FDA reported "no quality unit oversight" at the facility. The warehouse operated without any written Standard Operating Procedures (SOPs), including no procedures governing "receipt, storage, and distribution of APIs, environmental monitoring, handling of cold storage products, deviations, potential complaints, or recalls."
Officials at the site admitted that no transportation logs, training records, or batch tracking systems existed. Even the Corporate Quality Assurance Manager told FDA officials that he was "unaware of the practices and operations concerning APIs, intermediates, and raw materials" at the warehouse.
Severe Pest Infestations Among Drug Materials
In one of the most damning observations, the FDA documented extensive pest infestations and environmental contamination. "Multiple pest and animal sightings were observed within the two buildings of the warehouse. This included birds flying throughout the warehouse buildings, bird droppings on top of drums, birds' nest observed within the top seams of the warehouse, crawling lizards, and cats crawling in between pallets and rows of API and Intermediate drums."
Several drums were found damaged and open to the environment, stored near bird nests and droppings, with no system for pest control or container inspection in place.
Expired Materials Mixed with Fresh Inventory
Inspectors discovered "expired drums being commingled with recently dated 2025 material drums within the warehouse facility." The facility lacked any "procedure for segregation or quarantine of rejected, released, or quarantined material," compounded by the absence of FIFO (first-in, first-out) inventory management systems.
Uncontrolled Storage Environment
The FDA noted complete absence of environmental controls, stating: "There is no system or mechanism for monitoring temperature and humidity for APIs, intermediates, key starting materials, and raw materials stored throughout the warehouse. The buildings are open to the outside environment."
Additionally, certificates of analysis (CoAs) for stored materials were not available on-site, violating basic traceability requirements.
Regulatory Implications and Industry Impact
The Form 483 observations indicate potential violations of 21 CFR Part 211, which governs GMP for finished pharmaceuticals. Such findings often precede Warning Letters or import alerts, depending on the company's response and corrective action.
Hetero Labs is one of India's largest API and finished drug manufacturers supplying global markets, including the US. The FDA concluded that the "balance of convenience and irreparable harm" lies in immediate corrective action, calling on the firm to establish proper GMP oversight, documentation, and pest control protocols to prevent contamination and safeguard patient safety.
The inspection findings could have broad implications for Hetero Labs' global supply operations, particularly given the company's significant role in pharmaceutical manufacturing for international markets.